920289-92-5Relevant academic research and scientific papers
Development of a peptidomimetic antagonist of neuropeptide FF receptors for the prevention of opioid-induced hyperalgesia
Bihel, Frédéric,Humbert, Jean-Paul,Schneider, Séverine,Bertin, Isabelle,Wagner, Patrick,Schmitt, Martine,Laboureyras, Emilie,Petit-Demouliere, Beno?t,Schneider, Elodie,Mollereau, Catherine,Simonnet, Guy,Simonin, Frédéric,Bourguignon, Jean-Jacques
, p. 438 - 445 (2015)
Through the development of a new class of unnatural ornithine derivatives as bioisosteres of arginine, we have designed an orally active peptidomimetic antagonist of neuropeptide FF receptors (NPFFR). Systemic low-dose administration of this compound to rats blocked opioid-induced hyperalgesia, without any apparent side-effects. Interestingly, we also observed that this compound potentiated opioid-induced analgesia. This unnatural ornithine derivative provides a novel therapeutic approach for both improving analgesia and reducing hyperalgesia induced by opioids in patients being treated for chronic pain.
COMPOUND FOR PREPARATION OF ANTIBODY-PAYLOAD CONJUGATE AND USE THEREOF
-
, (2022/03/15)
The present application relates to a novel linker for use in bioconjugation, comprising two or more electrophilic carbon atoms of a carbonyl group, and a click chemistry functional group and, more specifically, to a linker through which a compound, a peptide, and/or a protein can be directly and/or indirectly linked by a substitution reaction to a desired target molecule, that is, a target molecule.
ORNITHINE- AND LYSINE-DERIVATIVES FOR THE TREATMENT OF PAIN
-
Page/Page column 34, (2014/01/07)
The invention relates to novel compounds, derivatives of ornithine or of lysine, to pharmaceutical compositions containing same and to the use of same in the treatment of pain.
Ornithine- and lysine-derivatives for the treatment of pain
-
Paragraph 0100, (2014/01/07)
The invention relates to novel compounds, derivatives of ornithine or of lysine, to pharmaceutical compositions containing same and to the use of same in the treatment of pain.
Glutamate aggrecanase inhibitors
-
Page/Page column 41; 55, (2008/06/13)
The present invention relates to modulators of metalloproteinase activity.
Design of peptidomimetic ligands for the pp60(src) SH2 domain
Plummer, Mark S.,Lunney, Elizabeth A.,Para, Kimberly S.,Shahripour, Aurash,Stankovic, Charles J.,Humblet, Christine,Fergus, James H.,Marks, James S.,Herrera, Roman,Hubbell, Susan,Saltiel, Alan,Sawyer, Tomi K.
, p. 41 - 47 (2007/10/03)
Potent ligands of the Src SH2 domain, discovered through structure-based drug design efforts, with the general structure Ac-pTyr-Glu-NRR' are disclosed.
